Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation

Completed · Phase 3 · Has a placebo group

Conditions studied: Cardiovascular Disease, Inflammation

In brief

The purpose of this study is to determine the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the inflammatory response to in vivo and ex vivo endotoxin challenge as measured by the production over time of several inflammatory markers.

Key facts

Study ID

NCT01078909

Run by

Penn State University

People needed

125

Starts

2011-10-01

Expected to finish

2014-04-01

Last updated by the study team

2023-08-21

Who can join

Age: 20 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men and non-pregnant/lactating women between the ages of 20 and 45
• BMI >19.9 and <30.0
• Able to give written informed consent and willing to comply with all study- related procedures.

You may not qualify if…

• Previous history of heart disease or diabetes
• Renal Insufficiency
• Chronic anti-inflammatory use
• Systolic blood pressure < 90
• Individuals currently using tobacco products or have done so in the previous 30 days
• Individuals taking Omega-3 fatty acid supplements or their usual intake of fish is greater than 3-4 servings per month.

Where it is running

• Penn State University — University Park, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.